Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of subcutaneous efgartigimod in active idiopathic inflammatory myopathy
NL-OMON58840Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Apr 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in Autoimmune Myopathies, sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Changes in safety assessments. Started Apr 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on NL-OMON58840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58840.